Popular
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
CME/CEEarlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
Oh, the Hats You'll Wear! The Many Modalities of Pediatric Obesity Management
CME/CEOh, the Hats You'll Wear! The Many Modalities of Pediatric Obesity Management
"I think we're the bridge between the healthcare systems, the pharma systems, and the molecular diagnostic systems," says Matt Newman with Manifold
The Convergence"I think we're the bridge between the healthcare systems, the pharma systems, and the molecular diagnostic systems," says Matt Newman with Manifold
Management of Elevated Albuminuria: Examining Therapeutic Pathways
Conversations in CV Risk AssessmentManagement of Elevated Albuminuria: Examining Therapeutic Pathways
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
CME/CEImplementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
Optimizing Care of the Hospitalized Patient With Overt Hepatic Encephalopathy
MinuteCE®Optimizing Care of the Hospitalized Patient With Overt Hepatic Encephalopathy
Programs
Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
CME/CEPrimary Care for the Brain: Prevention and Early Detection of Cognitive Decline
Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
CME/CESpotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
uACR and eGFR: A Dual-Marker Approach to Cardiovascular Risk Assessment
Conversations in CV Risk AssessmentuACR and eGFR: A Dual-Marker Approach to Cardiovascular Risk Assessment
"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
The Convergence"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
CME/CEIgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
Advances in the Treatment of Overt Hepatic Encephalopathy: What's in the Pipeline?
MinuteCE®Advances in the Treatment of Overt Hepatic Encephalopathy: What's in the Pipeline?
Clinical Practice
Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
CME/CEPatients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
The Link Between Albuminuria and CV Risk in Non-Diabetic Patients
Conversations in CV Risk AssessmentThe Link Between Albuminuria and CV Risk in Non-Diabetic Patients
The Role of Albuminuria in Assessing Cardiovascular Risk
Conversations in CV Risk AssessmentThe Role of Albuminuria in Assessing Cardiovascular Risk
Rethinking Chronic Kidney Disease: A Key Driver of Cardiovascular Risk
Conversations in CV Risk AssessmentRethinking Chronic Kidney Disease: A Key Driver of Cardiovascular Risk
Diagnosing IBS-C: From Clinical Clues to Confident Calls
Clinician's RoundtableDiagnosing IBS-C: From Clinical Clues to Confident Calls
Addressing Unmet Needs in Metastatic Uveal Melanoma
CME/CEAddressing Unmet Needs in Metastatic Uveal Melanoma
Doctors Lounge
Next-Gen Clinical Monitoring: Predicting Inpatient Decline with AI-Driven Alerts
The ConvergenceNext-Gen Clinical Monitoring: Predicting Inpatient Decline with AI-Driven Alerts
Death by Planet? Strange Diagnoses from 1632 London’s Medical Records
Rub Some Dirt In ItDeath by Planet? Strange Diagnoses from 1632 London’s Medical Records
Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
Project Oncology®Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
Uncovering Disparities in Teleneurology Utilization Post-Pandemic
On the Frontlines of Multiple SclerosisUncovering Disparities in Teleneurology Utilization Post-Pandemic
MS Management: Strategies for Ensuring Equitable Access to Teleneurology
On the Frontlines of Multiple SclerosisMS Management: Strategies for Ensuring Equitable Access to Teleneurology
Psoriasis Disparities Among Different Racial and Ethnic Groups
On the Frontlines of PsoriasisPsoriasis Disparities Among Different Racial and Ethnic Groups
CME
Taking Action Against RSV: No Child Unprotected
CME/CETaking Action Against RSV: No Child Unprotected
Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
CME/CEMuscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
Rethinking Schizophrenia Treatment Through Muscarinic Modulation
CME/CERethinking Schizophrenia Treatment Through Muscarinic Modulation
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
MinuteCE®Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
MinuteCE®Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
Breaking New Ground in mCRC: Exploring Novel Targets in mCRC
MinuteCE®Breaking New Ground in mCRC: Exploring Novel Targets in mCRC
Industry Feature
An Expert’s Approach to a Difficult-to-Manage Condition: Breaking the rCDI Cycle with a Microbiome-Focused Strategy
Medical Industry FeatureAn Expert’s Approach to a Difficult-to-Manage Condition: Breaking the rCDI Cycle with a Microbiome-Focused Strategy
Shared Decision-Making in Pulmonary Arterial Hypertension: Strategies for PAH Treatment Initiation and Support
Medical Industry FeatureShared Decision-Making in Pulmonary Arterial Hypertension: Strategies for PAH Treatment Initiation and Support
Navigating IgA Nephropathy: Pathogenesis, The Role Of APRIL & The 4-Hit Process, & A Patient Case Study
Medical Industry FeatureNavigating IgA Nephropathy: Pathogenesis, The Role Of APRIL & The 4-Hit Process, & A Patient Case Study
Operational Considerations for Bispecific T-Cell Engager Therapies
Medical Industry FeatureOperational Considerations for Bispecific T-Cell Engager Therapies
Early Referral in PMR Management and the Impact on Outcomes
Medical Industry FeatureEarly Referral in PMR Management and the Impact on Outcomes
New Trial Device Opens Blood-Brain Barrier to Treat Glioblastoma
Medical Industry FeatureNew Trial Device Opens Blood-Brain Barrier to Treat Glioblastoma